白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌的临床分析

发布时间：2018-11-19 11:35

【摘要】：目的:探讨白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌疗效、不良反应和生存情况。方法:选取经病理学诊断为卵巢上皮癌患者78例,既往使用过紫杉类、吉西他滨等药物治疗后进展,接受白蛋白结合型紫杉醇联合贝伐珠单抗方案治疗。具体方案:第1天接受白蛋白结合型紫杉醇260mg/m2、第2天接受贝伐珠单抗15mg/m2,21d为1个周期,每个周期评价不良反应,2个周期评价疗效。结果:78例患者均可进行疗效评价,无完全缓解病例,部分缓解9例,稳定42例,进展27例,有效率为11.5%(9/78),临床获益率为65.4%(51/78)。主要不良反应为骨髓抑制、消化道反应、乏力、脱发、外周神经毒性、皮疹、高血压、肌肉酸痛,不良反应多为I级和II级毒性,患者对毒副作用均可耐受,未发生治疗相关性死亡。结论:白蛋白结合型紫杉醇联合贝伐珠单抗治疗复发性卵巢癌可获得较好的疗效,不良反应可以耐受。
[Abstract]:Objective: to investigate the efficacy, adverse reaction and survival of albumin bound paclitaxel combined with bevacizumab in the treatment of recurrent ovarian cancer. Methods: 78 cases of ovarian epithelial carcinoma diagnosed by pathology were treated with taxol combined with bevacizumab. The specific scheme: on the first day, the albumin bound paclitaxel 260 mg / m ~ 2, the second day after receiving bevacizumab 15 mg 路m ~ (221) d as a cycle, each cycle to evaluate adverse reactions, 2 cycles to evaluate the efficacy. Results: all the 78 patients were evaluated. There were no complete remission, partial remission in 9, stable in 42, progress in 27. The effective rate was 11.5% (9 / 78), and the clinical benefit rate was 65.4% (51 / 78). The main adverse reactions were myelosuppression, digestive tract reaction, fatigue, alopecia, peripheral neurotoxicity, rash, hypertension, muscle soreness. No treatment-related death occurred. Conclusion: Albumin bound paclitaxel combined with bevacizumab is effective in the treatment of recurrent ovarian cancer and can be tolerated.
【作者单位】：哈尔滨医科大学附属第三医院妇科三病区;
【基金】：黑龙江省教育厅科学技术研究项目(编号:12531386)
【分类号】：R737.31

【相似文献】